12:00 AM
 | 
Jul 25, 2011
 |  BC Week In Review  |  Company News  |  Deals

Amira, Bristol-Myers deal

Bristol-Myers will acquire Amira for $325 million in cash, plus up to $150 million in milestones. Bristol-Myers will gain Amira's AM152, an oral lysophosphatidic acid receptor 1 ( LPA1) antagonist that has completed Phase I testing to treat lung fibrosis of scleroderma and idiopathic pulmonary fibrosis...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >